Real-World Long-Term Effectiveness of Fremanezumab in Patients With Migraine Who Switched From Another mAb Targeting the CGRP Pathway – Subgroup Analysis of the FINESSE Full Analysis (P10-12.009)
To evaluate real-world long-term data on the effectiveness of fremanezumab in patients with migraine who switched from a previous calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb).
Authors
- Lars Neeb (ORCID: https://orcid.org/0000-0002-1940-6399)
- Gregor Broessner
- Xenia Hamann
- Charly Gaul (ORCID: https://orcid.org/0000-0002-9362-3711)
- Torsten Kraya (ORCID: https://orcid.org/0000-0002-6060-3810)
- Andreas Straube (ORCID: https://orcid.org/0000-0003-0765-3760)
Institutions
- Innsbruck Medical University (AT)
- Klinikum St. Georg (DE)
- Cardiovascular Center Frankfurt (DE)
- Teva Pharmaceuticals (Germany) (DE)
- Universitätsklinikum Brandenburg an der Havel (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211972
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00